Artiva Biotherapeutics (ARTV) News
NASDAQ: ARTVHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
3.78-0.05 (-1.31%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARTV news summary
We found 3 recent headlines mentioning Artiva Biotherapeutics (ARTV): 0 in the past week and 3 in the past 30 days, most often from PR Newswire, Nasdaq, GlobeNewswire. For price context, ARTV is down 1.31% at $3.78. The most recent story, "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTV", was published by PR Newswire on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Artiva Biotherapeutics headlines
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTVNEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Artiva Biotherapeutics, Inc. ("Artiva" or the "Company") (NASDAQ: ARTV). Such investors are…PR Newswire
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals(RTTNews) - The biotech sector stayed active this week, with a mix of regulatory approvals, strategic partnerships, M&A activity, and clinical trial developments.NasdaqAARD, ABBV, ARTV, AZN
- Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®GlobeNewswire